tag:blogger.com,1999:blog-36634196.post2229418854261301386..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Talking of Sons-of-Drugs…Chris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36634196.post-18140843037398350482007-06-03T22:27:00.000-05:002007-06-03T22:27:00.000-05:00Sepracor started the chirality approach to drugs a...Sepracor started the chirality approach to drugs and although fundamentally the theory sounds appealing, the economic success has not given it right. Of course, the larger the molecule the more steric centers there are, begging the question, which center is the right one. Note that the discussed strategy of bait-and-switch was already applied by AstraZeneca for omeprazole Prilosec introducing Nexxium as replacement. There the pivotal clinical trial used 40mg Prilosec compared to 40mg Nexxium finding an improvement.<BR/>Would that have still been the case if using a 40 to 20 comparison assuming the isomer story holds true? AstraZeneca had in the course of Prilosec patents been found guilty by the EU of obstructing and misusing the patent laws...Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-37158438738087723872007-06-03T22:07:00.000-05:002007-06-03T22:07:00.000-05:00Sepracor was one of starters of the chirality appr...Sepracor was one of starters of the chirality approach and as of late not too many isomers were really succesful. In fact, one of the more high-profile cases omeprazole Prilosec and its isomer Nexxium is another case of less fullfiled expectations after a bait-and-switch. Fundamentally, the question may be asked, although the D/L theory does sound nice, how do we know which of the multiple steric centers in a given molecule is the right one. Of course the larger the molecule the more options...MichaelRShttps://www.blogger.com/profile/06301146223193975133noreply@blogger.com